Abstract
The market for N-glycosylated therapeutic proteins
represents multi-billion dollars in sales and is growing
more than 10% each year. This requires cost-effective
production platforms that display correct and homogeneous
N-glycosylation. Based on recent results, we
propose to use mushroom-forming basidiomycetes for
the production of N-glycosylated therapeutic proteins.